This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement / D. Goldsmith, A. Covic, M. Vervloet, M. Cozzolino, I. Nistor, F.T.C.K.D.B.D.W. Group, T.E.R.B.P.A. Board. - In: NEPHROLOGY DIALYSIS TRANSPLANTATION. - ISSN 0931-0509. - 30:5(2015 May), pp. 698-700. [10.1093/ndt/gfv050]
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement
M. Cozzolino;
2015
Abstract
This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ndt.gfv050.full.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
67.48 kB
Formato
Adobe PDF
|
67.48 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Nephrol. Dial. Transplant.-2015-Goldsmith-698-700.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
69.71 kB
Formato
Adobe PDF
|
69.71 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
